Stay updated on Azacitidine + Pembrolizumab in AML Clinical Trial
Sign up to get notified when there's something new on the Azacitidine + Pembrolizumab in AML Clinical Trial page.

Latest updates to the Azacitidine + Pembrolizumab in AML Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoNo Change Detected
- Check16 days agoChange DetectedUpdated the page’s software/revision version indicator from v3.5.2 to v3.5.3.SummaryDifference0.1%

- Check24 days agoChange DetectedPage revision updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check52 days agoChange DetectedAdded Revision: v3.5.0 and removed Revision: v3.4.3.SummaryDifference0.1%

- Check67 days agoChange DetectedSite revision label updated from v3.4.2 to v3.4.3 in the page header/footer.SummaryDifference0.1%

- Check89 days agoChange DetectedRevision: v3.4.2 was applied, replacing the previous v3.4.1. No substantive study information or user-facing content was changed.SummaryDifference0.1%

- Check96 days agoChange DetectedPage revision updated from v3.4.0 to v3.4.1, which does not alter the study details, inclusion criteria, or outcome measures. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Azacitidine + Pembrolizumab in AML Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Azacitidine + Pembrolizumab in AML Clinical Trial page.